A Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran

ConclusionThe majority of patients enrolled either did not experience GIS at all, or their GIS resolved using either one individually, or a combination of the two strategies described.Trial registrationhttp://www.ClinicalTrials.gov identifier: NCT01493557.

http://link.springer.com/10.1007/s40119-016-0071-5

Source: Cardiology and Therapy - October 4, 2016 Category: Cardiology Source Type: research